Thermo Fisher Opens Bioprocess Design Center to Accelerate Therapy Development

Thermo Fisher Scientific Inc. (NYSE:TMO) announced the opening of its new Bioprocess Design Center in Plainville, Massachusetts, on April 28, 2026. The facility is designed to accelerate the development of life-changing therapies by enabling customers to partner with the company's experts to optimize bioprocessing.

The Product

The center is a state-of-the-art facility aimed at helping biotech and pharmaceutical companies improve their production processes. Customers can work alongside Thermo Fisher scientists to test and scale up bioprocessing, reducing the time and cost required for therapy development.

Pricing and Availability

The company has not disclosed pricing details or usage fees. However, the center is expected to be available to current and potential customers through contractual arrangements.

Competition

Thermo Fisher faces competition from companies like Danaher (DHR) and Merck KGaA in the bioprocessing space. The new design center could provide a competitive edge by offering integrated consulting and testing services.

Potential Impact on the Company

The center is expected to strengthen Thermo Fisher's position as a key partner in the bioprocessing supply chain, potentially boosting revenue from service contracts and consumables. The stock is also among billionaire Steve Cohen's top large-cap picks, reflecting confidence in the company's growth prospects.